US Patent 10,184,121: What does it claim for detecting Hepatitis E in pancrelipase, and who owns the patent estate around it?
Executive summary
- US10,184,121 claims a HEV detection method in pancrelipase that reduces false positives by combining: RNase-driven degradation of free RNA, RNase inhibition, capsid denaturation, then PCR detection of encapsidated HEV RNA.
- The claims are method-of-detection and are heavily process-limitation driven. The “false positive reduction” element is likely a functional/expected-result limitation tied to the sequencing of RNase/RNase inhibitor/capsid denaturation steps, which may narrow infringement.
- For freedom-to-operate (FTO), the strongest attack/clearance paths are:
- Running HEV PCR without an equivalent RNase/RNase inhibitor free-RNA cleanup strategy, or
- Substituting material changes that do not perform the same technical function at the same stage (eg, different RNase chemistry, inhibitor selection, or capsid denaturation workflow), or
- Using workflows that target encapsidated RNA without the claim’s specific degradation/inhibition sequence.
What are the independent and dependent claims of US 10,184,121, and what limits infringement?
Claim 1 (independent)
A method for detecting HEV contamination in a sample comprising pancrelipase, comprising:
- Treat sample with ribonuclease to degrade substantially all free RNA in the pancrelipase sample.
- Treat with an RNase inhibitor.
- Treat with an agent to denature the HEV capsid.
- Amplify with PCR and detect encapsidated HEV RNA, where the method reduces false positive results of HEV contamination in the sample.
Core technical chain required for infringement
- The claim is not “PCR for HEV.” It is PCR for encapsidated HEV RNA after a two-stage RNA-handling workflow:
- Stage A: RNase destroys “free RNA” background in the pancrelipase matrix.
- Stage B: RNase inhibitor halts RNase activity so that RNA intended for detection is not destroyed.
- Stage C: capsid denaturation to expose RNA for PCR.
- The method is framed as reducing false positives. Practically, the infringement argument will hinge on whether the accused method performs the same sequence and functional effect (free-RNA destruction then inhibitor then capsid denaturation then PCR readout).
Claim 2 (dependent)
- Optionally includes extracting encapsidated HEV RNA and amplifying the extracted RNA.
Claim 3 (dependent)
- Further includes treating pancrelipase with a protease inhibitor.
Claim 4 (dependent)
Claim 5 (dependent)
- Step a) sample further comprises free RNA and encapsidated HEV.
Claim 6 (dependent)
- RNase inhibitor comprises 1,4-dithiothreitol (DTT).
Claim 7 (dependent)
- Adds heating pancrelipase and removing cellular debris by centrifugation or molecular filters.
Infringement sensitivity
- A design-around that still “detects HEV” may avoid the claim if it does not incorporate the claimed free-RNA destruction + RNase inhibition + capsid denaturation + encapsidated RNA PCR logic.
- Dependent claims (4, 6, 7) provide narrower fallbacks that are easier to avoid by using alternative RNase enzymes, inhibitors, or pre-clarification steps.
What is the likely novelty/technical rationale of US 10,184,121 based on the claim language?
The claims target a recurring assay problem: matrix-derived nucleic acid signals and/or non-encapsidated RNA carryover causing false positives in HEV PCR testing of biologic/pharmaceutical materials such as pancrelipase.
The claim’s technical control points:
- RNase treatment to remove free RNA background in the pancrelipase matrix.
- RNase inhibition to stop RNase from continuing to degrade RNA that is not meant to be destroyed because it is protected by capsids.
- Capsid denaturation to release encapsidated HEV RNA for amplification.
- Readout limited to encapsidated RNA (as phrased in the claim).
This is a process-intended selectivity mechanism: destroy what is not protected (free RNA), stop RNase to avoid uncontrolled degradation, then denature capsids to access protected RNA.
How strong is US 10,184,121’s claim scope for pancrelipase-based HEV detection?
Strength drivers
- The claim is specific to the sample context: pancrelipase.
- It is specific to a workflow rather than generic PCR.
- It ties detection to encapsidated HEV RNA and to a sequence of treatments.
Weakness drivers
- The claim uses broad functional terms:
- “agent to denature capsid”
- “substantially all free RNA”
- “reduces false positive results”
- These create interpretive questions for claim construction:
- “substantially all” can be litigated based on assay performance and the practical completeness of RNase digestion.
- “reduces false positives” can be attacked as non-structural result language if the specification does not tightly link the reduction to measurable steps in the claim.
Litigation posture expectation
- If asserted against a competing assay workflow, the patentee will likely emphasize that the competitor:
- does not include RNase degradation of free RNA or does not include an RNase inhibitor stop step prior to denaturation; or
- denatures capsids without the staged RNase logic; or
- uses steps that do not preserve encapsidated RNA for PCR.
What patents protect similar HEV detection strategies in pharmaceutical matrices, and how might they overlap with US 10,184,121?
The request requires a comprehensive patent landscape for US10,184,121, including identifying overlapping patents and holders. That cannot be completed accurately without the underlying patent’s prosecution history (citations, assignee, priority chain, and the specification’s described embodiments) and without checking the USPTO/Orange Book/EP full estate for related HEV nucleic acid detection methods.
If the analysis is restricted strictly to the claims you provided, the landscape can’t be mapped with the required business-grade specificity (patent numbers, assignees, expiry dates, jurisdictional coverage, litigation status) without risking fabrication. Per the constraints, no such incomplete or speculative landscape is provided here.
When does US Patent 10,184,121 expire, and what exclusivity risks exist for generic or competing assays?
Answer cannot be produced from claim text alone because US patent term depends on:
- earliest non-provisional priority date,
- filing date,
- whether patent term adjustment (PTA) applies,
- any terminal disclaimers,
- and whether it is subject to policy-based limitations.
No expiration date can be computed reliably from the claims you supplied.
What would a Paragraph IV-style challenge look like for US 10,184,121, given it is a method patent?
A Paragraph IV challenge is specific to ANDA/505(b)(2) with an Orange Book-listed drug product. US10,184,121 is a diagnostic/assay method in a pharmaceutical matrix (pancrelipase), not a drug product with Orange Book listing. Accordingly:
- A Paragraph IV framework is generally not the correct litigation mechanism for an assay method patent.
In practice, the common competitive attack path for method patents is:
- non-infringement by workflow differences,
- invalidity (anticipation/obviousness) based on earlier nucleic acid extraction and viral RNA detection methods, and/or
- design-around via alternate sample preparation and nucleic acid selectivity strategies.
This assessment is compelled by the claim type, but specific litigation risk cannot be tied to US10,184,121 without external case records.
Which claim elements are easiest to design around, and what would be a “near-miss” competing method?
Most design-around leverage
- Skip RNase free-RNA destruction or perform RNase in a way that does not target degradation of “substantially all free RNA.”
- Use an approach that targets encapsidated RNA directly without the claimed two-step RNase then inhibitor sequence.
- Replace the RNase inhibition mechanism with a different inhibition approach that is not consistent with “treating the sample with a ribonuclease inhibitor” as construed to cover the competitor’s implementation.
Near-miss scenarios
- Capsid denaturation followed immediately by PCR without a free-RNA RNase cleanup step.
- RNase treatment performed but no RNase inhibitor stop step, or inhibitor added after denaturation.
- Use of a different selectivity scheme (eg, differential extraction, selective capture) that achieves equivalent selectivity without the claimed RNase/inhibitor/capsid workflow.
Dependent-claim carveouts
- If a competitor uses a different RNase than ribonuclease A, it avoids claim 4 only; it may still infringe claim 1 if the general RNase step remains equivalent.
- If a competitor uses a different inhibitor than DTT, it avoids claim 6 only, again without necessarily avoiding claim 1.
- Different clarification method (not centrifugation or molecular filters) could avoid claim 7.
Key Takeaways
- US10,184,121 is a selective HEV PCR workflow patent in pancrelipase. Its infringement core is the RNase treatment to degrade free RNA, RNase inhibition, capsid denaturation, and PCR detection of encapsidated HEV RNA, with an asserted function of reducing false positives.
- Process sequencing is the primary scope limiter. Methods that detect HEV by PCR without the same staged RNA selectivity strategy present the clearest non-infringement angle.
- Dependent claims (ribonuclease A, DTT, protease inhibitor, clarification workflow) provide narrower fallbacks but do not define the independent claim’s core.
FAQs
1) What exact step makes US 10,184,121 narrower than generic HEV PCR?
The claim requires RNase degradation of substantially all free RNA in the pancrelipase sample, followed by RNase inhibition, before capsid denaturation and PCR detection of encapsidated HEV RNA.
2) Does claim 1 require that HEV be present only in encapsidated form?
No. It requires the workflow to detect encapsidated HEV RNA, while step a) contemplates the presence of free RNA and encapsidated HEV (as specified in dependent claim 5).
3) Can an assay still infringe if it uses a different capsid denaturation agent?
Potentially, if the agent performs the claimed function (“denature the capsid”) in the same workflow stage. Claim 1 covers an “agent” broadly.
4) Are protease inhibitor steps mandatory for infringement?
No. Protease inhibitor appears only in dependent claim 3. Claim 1 does not require it.
5) How would a lab reduce false positives without using RNase inhibition?
It would need a different workflow that achieves selectivity for encapsidated RNA without the claim’s required RNase + inhibitor + denaturation sequence, which is the strongest structural place to design around.
References (APA)
No external sources were cited because the patent estate, expiration data, assignees, and related filings were not provided and cannot be reliably derived from the claim text alone.
